ABBOTT LABORATORIES WKN: 850103 ISIN: US0028241000 Kürzel: ABT Forum: Aktien Thema: Hauptdiskussion

$ABT | Abbott Labs Q2 2025 Earnings - Net Sales $11.14B (est $11.06B) - Adj EPS $1.26 (est $1.25) - Organic Sales +6.9% (est +7.03%) - Sees Q3 Adj EPS $1.28 To $1.32 (est $1.34) - Sees FY Adj EPS $5.10 To $5.20, Saw $5.05 To $5.25

$ABT | Abbott Labs Q1 2025 Earnings - Adj EPS $1.09 (est $1.07) - Net Sales $10.36B (est $10.4B) - Reaffirms FY Guidance - Still Sees FY Adj EPS $5.05 To $5.25 (est $5.15) - Sees Q2 Adj EPS $1.23 To $1.27 (est $1.25)

Aus meiner Sicht Ausbruch nach oben, nach längerer Seitwärtsphase

🥳🚀😂

Abbott Labs reports robust Q4 & 2024 results: $11B Q4 sales (+7.2%), $42B full-year (+4.6%). Strong organic growth in base business. 2025 outlook positive with 7.5-8.5% organic sales growth projected. 404th consecutive quarterly dividend declared

ABBOTT, RECKITT NOT LIABLE IN TRIAL OVER CLAIMS THAT PREMATURE INFANT FORMULA CAUSED DEBILITATING ILLNESS, JURY FINDS

Abbott Laboratories reported Q3 revenues of $10.63 billion: a +5% Y/Y growth and ~1% above consensus estimates. 🔹Operating margin expanded 0.51 p.p. Y/Y to 23.4%, roughly in line with the 23.4% expectation. 🔹EPS (non-GAAP) was $1.21: a +6% Y/Y increase, and 1% above consensus estimates.

#Abbott Laboratories $ABT #Earnings: - Q3 Non-GAAP EPS of $1.21 beats by $0.01. - Revenue of $10.64B (+4.9% Y/Y) beats by $90M.

Echt stark heute dieses Momentum

Hat sicher aber schnell wieder erholt 🤠

https://www.diepresse.com/18707239/unreine-babynahrung-abbott-muss-95-millionen-dollar-zahlen Das könnte den Kurs kurzfristig weiter belasten

Finds gut, brauch eh noch paar Stückchen👌

Erwartungen übertroffen, Jahresprognose angehoben, Kurs sinkt 😂 Börse…

Positiv: Total Q2 2024 sales of $10.4 billion, a 4.0% increase. Organic sales growth of 9.3%. GAAP diluted EPS of $0.74; adjusted EPS of $1.14. Raised full-year 2024 EPS guidance to $3.30-$3.40 (GAAP) and $4.61-$4.71 (adjusted). FDA approval for Esprit™ BTK and two new continuous glucose monitoring systems. CE Mark for AVEIR® dual chamber leadless pacemaker. Medical Devices sales increased by 10.2%, with 12.1% organic growth. Diabetes Care sales up 18.4% reported and 20.4% organically. 10 new growth opportunities from R&D pipeline in H1 2024.

- Second-quarter GAAP diluted EPS of $0.74 and adjusted diluted EPS of $1.14, which excludes specified items. - Sales of $10.4 billion - Abbott raised its full-year 2024 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.30 to $3.40 and projects adjusted diluted EPS of $4.61 to $4.71. "We achieved another quarter of strong growth in our underlying base business," said Robert B. Ford, chairman and chief executive officer, Abbott. "We have a lot of positive momentum heading into the second half of the year and are raising our full-year guidance."